RecruitingNCT03979170

Patient-derived Organoids of Lung Cancer to Test Drug Response

Sponsor

University Hospital, Geneva

Enrollment

50 participants

Start Date

Apr 1, 2019

Study Type

OBSERVATIONAL

Conditions

Lung Cancer Organoid

Summary

This is a single center, single arm, open and exploratory clinical study, with 50 cases planned for a period of 3 years. The purpose of this study is to evaluate the consistency and accuracy of a Patient-Derived Organoid (PDO) Model of lung cancer to predict the clinical efficacy of anti-cancer drugs, in order to predict the best chemotherapy regimen for each given patient.

Eligibility

Min Age: 18 Years

Plain Language Summary

Simplified for easier understanding

This study grows miniature replicas of a patient's own lung cancer in the lab (called organoids) from biopsied tissue, then tests how these mini-tumors respond to different drugs. The goal is to personalize cancer treatment by predicting which drugs will work best for each patient. **You may be eligible if...** - You are 18 or older - You have confirmed lung cancer - You are able to have a biopsy or surgery to provide a tumor sample - You have given written informed consent **You may NOT be eligible if...** - You are under 18 - You are unable to give informed consent - You cannot have a biopsy or tumor sample taken - There is not enough tissue available for both the study and standard pathology review Talk to your doctor to see if this trial is right for you.

This summary was AI-generated to explain the trial in plain language. It is not medical advice. Always discuss eligibility with your doctor before enrolling in a clinical trial.

Interested in this trial?

Get notified about updates and connect with the research team.